CO2023005189A2 - Compuestos de heteroarilo fusionado y su uso como inhibidores de camkii - Google Patents
Compuestos de heteroarilo fusionado y su uso como inhibidores de camkiiInfo
- Publication number
- CO2023005189A2 CO2023005189A2 CONC2023/0005189A CO2023005189A CO2023005189A2 CO 2023005189 A2 CO2023005189 A2 CO 2023005189A2 CO 2023005189 A CO2023005189 A CO 2023005189A CO 2023005189 A2 CO2023005189 A2 CO 2023005189A2
- Authority
- CO
- Colombia
- Prior art keywords
- fused heteroaryl
- heteroaryl compounds
- camkii
- present
- camkii inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063084217P | 2020-09-28 | 2020-09-28 | |
| PCT/US2021/052025 WO2022067082A1 (en) | 2020-09-28 | 2021-09-24 | Fused heteroaryl compounds and their use as camkii inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023005189A2 true CO2023005189A2 (es) | 2023-08-09 |
Family
ID=80821052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0005189A CO2023005189A2 (es) | 2020-09-28 | 2023-04-24 | Compuestos de heteroarilo fusionado y su uso como inhibidores de camkii |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11795172B2 (enExample) |
| EP (1) | EP4216948A4 (enExample) |
| JP (1) | JP7824282B2 (enExample) |
| KR (1) | KR20230107551A (enExample) |
| CN (1) | CN116940354A (enExample) |
| AU (1) | AU2021350015A1 (enExample) |
| CA (1) | CA3196946A1 (enExample) |
| CL (1) | CL2023000894A1 (enExample) |
| CO (1) | CO2023005189A2 (enExample) |
| IL (1) | IL301480A (enExample) |
| MX (1) | MX2023003610A (enExample) |
| PE (1) | PE20240148A1 (enExample) |
| TW (1) | TW202229273A (enExample) |
| WO (1) | WO2022067082A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7824282B2 (ja) * | 2020-09-28 | 2026-03-04 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 |
| WO2023134692A1 (zh) * | 2022-01-13 | 2023-07-20 | 浙江同源康医药股份有限公司 | 多环类化合物及其用途 |
| CN115160235B (zh) * | 2022-08-10 | 2023-12-15 | 宜宾学院 | 一种2,3-二氢喹唑啉-4(1h)-酮类化合物及其超声合成方法 |
| US20250145630A1 (en) * | 2023-11-07 | 2025-05-08 | Cardurion Pharmaceuticals, Inc. | Polymorphs of a pyridinylimidazo[1,2-b]pyridazine |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1317266A2 (en) | 2000-08-08 | 2003-06-11 | Ortho-McNeil Pharmaceutical, Inc. | Neuroprotective 2-pyridinamine compositions and related methods |
| HK1054393B (en) | 2000-09-20 | 2009-08-28 | Ortho-Mcneil Pharmaceutical, Inc. | Pyrazine derivatives as modulators of tyrosine kinases |
| US20030187026A1 (en) * | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| JP2007504229A (ja) | 2003-09-02 | 2007-03-01 | メルク エンド カムパニー インコーポレーテッド | 代謝調節型グルタミン酸受容体−５のモジュレーターとしてのビピリジルアミン類およびエーテル類 |
| US7776857B2 (en) | 2007-04-05 | 2010-08-17 | Amgen Inc. | Aurora kinase modulators and method of use |
| US9216173B2 (en) | 2011-10-05 | 2015-12-22 | Merck Sharp & Dohme Corp. | 2-Pyridyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors |
| HRP20180037T1 (hr) | 2012-04-17 | 2018-03-23 | Fujifilm Corporation | Heterociklični spoj koji sadrži dušik ili njegovu sol |
| CA2894126A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CN107074856A (zh) * | 2014-09-05 | 2017-08-18 | 阿略斯泰罗斯医疗公司 | CaMKII抑制剂及其用途 |
| AR110252A1 (es) | 2016-11-30 | 2019-03-13 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam |
| CN110799190B (zh) | 2017-03-27 | 2024-04-19 | 卡都瑞恩医药有限公司 | 杂环化合物 |
| JP7447098B2 (ja) | 2018-09-25 | 2024-03-11 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | アミノピリミジン化合物 |
| WO2020068846A1 (en) * | 2018-09-25 | 2020-04-02 | Heterocyclic Compound | Heterocyclic compound |
| US20230000842A1 (en) | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
| JP7824282B2 (ja) * | 2020-09-28 | 2026-03-04 | カーデュリオン・ファーマシューティカルズ・インコーポレイテッド | 縮合ヘテロアリール化合物およびＣａＭＫＩＩ阻害剤としてのその使用 |
-
2021
- 2021-09-24 JP JP2023519291A patent/JP7824282B2/ja active Active
- 2021-09-24 WO PCT/US2021/052025 patent/WO2022067082A1/en not_active Ceased
- 2021-09-24 EP EP21873547.0A patent/EP4216948A4/en active Pending
- 2021-09-24 CN CN202180079818.5A patent/CN116940354A/zh active Pending
- 2021-09-24 CA CA3196946A patent/CA3196946A1/en active Pending
- 2021-09-24 US US17/485,137 patent/US11795172B2/en active Active
- 2021-09-24 PE PE2023001229A patent/PE20240148A1/es unknown
- 2021-09-24 AU AU2021350015A patent/AU2021350015A1/en active Pending
- 2021-09-24 TW TW110135508A patent/TW202229273A/zh unknown
- 2021-09-24 KR KR1020237014351A patent/KR20230107551A/ko active Pending
- 2021-09-24 IL IL301480A patent/IL301480A/en unknown
- 2021-09-24 MX MX2023003610A patent/MX2023003610A/es unknown
-
2023
- 2023-03-28 CL CL2023000894A patent/CL2023000894A1/es unknown
- 2023-04-24 CO CONC2023/0005189A patent/CO2023005189A2/es unknown
- 2023-08-28 US US18/238,949 patent/US12528816B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021350015A1 (en) | 2023-06-08 |
| EP4216948A1 (en) | 2023-08-02 |
| JP7824282B2 (ja) | 2026-03-04 |
| CN116940354A (zh) | 2023-10-24 |
| IL301480A (en) | 2023-05-01 |
| US12528816B2 (en) | 2026-01-20 |
| US20220098207A1 (en) | 2022-03-31 |
| JP2023543038A (ja) | 2023-10-12 |
| CL2023000894A1 (es) | 2023-09-15 |
| PE20240148A1 (es) | 2024-02-06 |
| AU2021350015A9 (en) | 2024-10-03 |
| MX2023003610A (es) | 2023-07-20 |
| TW202229273A (zh) | 2022-08-01 |
| CA3196946A1 (en) | 2022-03-31 |
| WO2022067082A1 (en) | 2022-03-31 |
| US20240182474A1 (en) | 2024-06-06 |
| KR20230107551A (ko) | 2023-07-17 |
| US11795172B2 (en) | 2023-10-24 |
| EP4216948A4 (en) | 2024-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023005189A2 (es) | Compuestos de heteroarilo fusionado y su uso como inhibidores de camkii | |
| ECSP20035590A (es) | Derivado de oxi-fluoropiperidina como inhibidor de quinasa | |
| CL2020000886A1 (es) | Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih. | |
| DOP2020000109A (es) | Derivado de amino-flocoropiperidina como inhibidor de quinasa | |
| CL2018001145A1 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| MX2022005679A (es) | Nuevos derivados que tienen una fraccion de 2,3-dihidro-1h-indeno o 2,3-dihidrobenzofurano o una sal farmaceuticamente aceptable de los mismos y composiciones farmaceuticas que los comprenden. | |
| DOP2020000111A (es) | Derivado de amino-metil piperidina como inhibidor de quinasa | |
| WO2015073922A3 (en) | Inhibition of oxidative stress in atrial fibrillation | |
| MX2018009248A (es) | Combinacion de monitoreo electronico con terapia farmacologica inhalada para manejar arritmias cardiacas incluyendo fibrilacion auricular. | |
| CO2022011388A2 (es) | Inhibidores heterocíclicos de pad4 | |
| BR112021017620A2 (pt) | Compostos macrocíclicos | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| AU2018246053A8 (en) | IP6K inhibitors | |
| DOP2024000102A (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa | |
| BR112022018929A2 (pt) | Inibidores da ciclofilina e seus usos | |
| PE20110432A1 (es) | Etexilato de dabigatran o una sal del mismo | |
| CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| CL2022000781A1 (es) | Tratamientos cognitivos medicinales | |
| MX2018014022A (es) | Derivado de 5h-pirrolo[2,3-d]pirimidin-6(7h)-ona novedoso. | |
| GEP20217332B (en) | 7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof | |
| CL2019002025A1 (es) | Derivados de pirrolotriazina como inhibidor de cinasas. | |
| MX2021003516A (es) | Compuesto de aminopirimidina. | |
| AR105752A1 (es) | Métodos para el tratamiento de enfermedades cardiovasculares | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer |